Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US/China-based MicuRx Gets $55m Series C Funding For MRX-I Antibiotic

US-Money-and-Pills_V2_1200x675

Related Content

Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing

Aug 23 2013

Related Companies

Shanghai MicuRx Pharmaceuticals Co., Ltd.

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

China Asia Pacific Clinical Trials Financing Commercial Infectious Diseases BioPharmaceutical

More from China

More from Focus On Asia

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window